Evaluating the Effectiveness of COVID-19 Vaccination for over 13-Weeks Pregnant Women: Among the First to Vaccinate Against Covid-19 in Vietnam

Abstract

Objective: Evaluating the effectiveness of COVID-19 Vaccination for over 13-week pregnant women, where were among the first to vaccinate against COVID-19. Method: Study on the Women who are pregnant over 13 weeks have not received the Covid-19 vaccine. Using Prizer’s Covid-19 Vaccine for women who are pregnant over 13 weeks. This pregnant woman needs to be thoroughly screened before the injection. The subjects were given pregnancy ultrasound, pregnancy heartbeat measurements before and after the vaccine injection. Study duration from 11/2021 – 12/2022 divided into three stages. Result: 230 pregnancy women were injected with Prizer’s Covid-19 vaccine, the average pregnancy age was 22.97 ± 11.55 weeks, the rate of premature pregnancy weeks showed that the number of pre-born babies accounted for 1.74%, there were no babies (0%) in 22-28 weeks and in 28-32 weeks, child in 32-35 weeks 0.43%, and babies in 35-37 week account for 1.3%. There were no newborns weighing < 2500 g (0%) for the weight of the pre-natal child, young borns with a weight of between 2500 and 3000 g accounted for 0.87%, and babies with a mass of > 3000 g and above accounted also for 0.87%. An anaphylactic history accounted for 2.61% having an allergic history, of which 0.87% women had a history of allergies to weather, changing environment; history of each drug allergy accounting for 1.74%, with an allergia to an analgesic of degree I (0.43%). Conclusion: It’s reasonable, safe, scientifically based, and safe for both mother and child to inject COVID-19 into pregnant women over 13 weeks.